Sign in

NUMD on OTC

Nu-Med Plus, Inc.

Nu-Med Plus, Inc. is an American surgical and medical instruments and apparatus company.1 It is headquartered in Port Jefferson, New York.1 Its shares trade on OTC under the symbol NUMD.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerNUMD on OTC1
  • IndustrySurgical & Medical Instruments & Apparatus1
  • HeadquartersPort Jefferson, New York1
  • Incorporated inUT2
  • Business address640 Belle Terre Rd. 2 E, Port Jefferson, Ny 117772
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

FDA approval prior to initiating sales in the United States and the approval of similar international agencies in their respective countries.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2020

-429.5%Return on equity4

Financial statements

Revenue5$0 in 2020
02019: $0$020192020: $0$02020
Operating income56-$2.0M in 2020+96% since 2019
-$2.0M-$1.5M-$1.0M-$500.0K02019: -$1.0M-$1.0M20192020: -$2.0M-$2.0M2020+96%
Net income56-$2.0M in 2020+94% since 2019
-$3.0M-$2.0M-$1.0M02019: -$1.0M-$1.0M20192020: -$2.0M-$2.0M2020+94%

Every line of the income statement as filed: the last 2 fiscal years, latest first.9

Period ending2025-12-312024-12-31
General and administrative expense$23.1K$34.3K
Rent expense$58$300
Professional and consulting fees$25.8K$28.7K
Total operating expenses$49.0K$63.3K
Operating loss-$49.0K-$63.3K
Interest expense-$7.2K-$5.0K
Total other income (expense)-$7.2K-$5.0K
Loss before income taxes-$56.2K-$68.3K
Net loss-$56.2K-$68.3K
Basic earnings per share$0.00$0.00
Diluted earnings per share$0.00$0.00
Weighted average common shares outstanding - basic (in Shares)83.5M shares83.5M shares
Weighted average common shares outstanding - diluted (in Shares)83.5M shares83.5M shares

Compare Nu-Med Plus, Inc. with another company

Corporate structure

Nu-Med Plus, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Nu-Med Plus, Inc.

  • Fred Tejada Filed SCHEDULE 13D on Nu-Med Plus, Inc., latest Aug 25, 2026
  • Nu-Med Plus, Inc. Port Jefferson, New York

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Nu-Med Plus, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$83.9K11 Dec 31, 2024$83.9K11 Dec 31, 20230%
Accumulated depreciation$83.9K9 Dec 31, 2025$83.9K9 Dec 31, 20240%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$2.4K11 Dec 31, 2024$6.8K11 Dec 31, 2023−65.1%

Properties, in its own words

NU-MED’s corporate office is at 640 Belle Terre Rd., Building E 2, Port Jefferson, NY 11777. Our R&D facility is located at 5718 W Dannon Way, Suite B, West Jordan, UT 84081. The executive office arrangement provides us the flexibility to expand our corporate offices as needed, without being committed to long-term overhead for office space we currently do not need. Our executive office and laboratory space are currently being provided to the Company at no cost. Management believes these facilities will serve our purposes for at least the next twelve months.

Item 2 of the 10-K filed Apr 15, 2026.3

Leadership

Who has led Nu-Med Plus, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Jeffrey Lynn Robins2013
  2. William C. Hayde2022–2023

Chief financial officer

  1. Keith L. Merrell2023
201520202025
Board members and other officers (13)

Timeline

  1. Aug 25, 20268-K Entered a material agreement; Completed an acquisition or sale; Unregistered sale of shares20
  2. Jul 10, 20268-K Entered a material agreement; Completed an acquisition or sale; Unregistered sale of shares21
  3. Jun 30, 20268-K Entered a material agreement; Unregistered sale of shares; Change to shareholders' rights22
  4. Oct 30, 20248-K Completed an acquisition or sale; Unregistered sale of shares; Change in control23
  5. May 2, 20248-K Completed an acquisition or sale; Unregistered sale of shares; Change in control24
  6. Apr 29, 20248-K Entered a material agreement25
  7. May 24, 20238-K Entered a material agreement; New debt or obligation26
  8. Feb 21, 20238-K Change of auditor27
  9. Nov 22, 2022New chief executive William C. Hayde becomes CEO12
  10. Nov 22, 20228-K Entered a material agreement28
  11. Nov 22, 20228-K Entered a material agreement29
  12. Oct 21, 20228-K Executive or director change30
  13. Sep 13, 20228-K Executive or director change31
  14. Feb 11, 2013New chief executive Jeffrey Lynn Robins becomes CEO13

Filings

45 filings to the SEC since October 2021: 7 annual reports, 15 quarterly reports, 13 major events, 6 insider forms, 1 large holders, 3 other. The latest 20:

  1. Aug 25, 2026SCHEDULE 13D EDGAR
  2. Aug 25, 20264 EDGAR
  3. Aug 25, 20263 EDGAR
  4. Aug 25, 20268-K EDGAR
  5. Aug 14, 202610-Q EDGAR
  6. Jul 10, 20268-K EDGAR
  7. Jun 30, 20268-K EDGAR
  8. May 14, 202610-Q EDGAR
  9. Apr 15, 202610-K ANNUAL REPORT ON FORM 10K FOR THE YEAR ENDED DECEMBER 31, 2025 EDGAR
  10. Mar 31, 2026NT 10-K REQUEST FOR AN EXTENSION OF TIME TO FILE OUR ANNUAL REPORT ON FORM 10K FOR THE Y EDGAR
  11. Nov 14, 202510-Q QUARTERLY REPORT ON FORM 10Q FOR THE QUARTER ENDED SEPTEMBER 30, 2025 EDGAR
  12. Aug 11, 202510-Q QUARTERLY REPORT ON FORM 10Q FOR THE QUARTER ENDED JUNE 30, 2025 EDGAR
  13. May 22, 202510-Q QUARTERLY REPORT ON FORM 10Q FOR THE QUARTER ENDED MARCH 31, 2025 EDGAR
  14. Mar 31, 202510-K ANNUAL REPORT ON FORM 10K FOR THE YEAR ENDED DECEMBER 31, 2024 EDGAR
  15. Nov 14, 202410-Q QUARTERLY REPORT ON FORM 10Q FOR THE QUARTER ENDED SEPTEMBER 30, 2024 EDGAR
  16. Oct 30, 20248-K CURRENT REPORT ON FORM 8-K DATED OCTOBER 28, 2024 EDGAR
  17. Aug 21, 202410-Q QUARTERLY REPORT ON FORM 10Q FOR THE QUARTER ENDED JUNE 30, 2024 EDGAR
  18. Aug 14, 2024NT 10-Q REQUEST FOR AN EXTENSION OF TIME TO FILE OUR QUARTERLY REPORT ON FORM 10Q FOR TH EDGAR
  19. May 15, 202410-Q QUARTERLY REPORT ON FORM 10Q FOR THE QUARTER ENDED MARCH 31, 2024 EDGAR
  20. May 2, 20248-K CURRENT REPORT ON FORM 8-K DATED APRIL 28, 2024 EDGAR

The 45 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Nu-Med Plus, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARNu-Med Plus, Inc.1
  • CIK0001543637
  • Employer ID (EIN)45-36725303
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company3
  • Incorporated inUtah3
  • Fiscal year endsDecember 311
  • Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address640 Belle Terre Rd. 2 E, Port Jefferson, NY 117771
  • Phone631-403-43371
  • Shares outstanding83,548,469 as of Aug 14, 20267
  • Public float$3.2M as of Jun 30, 20253
  • AuditorFruci & Associates II, PLLC, Spokane, Washington PCAOB ID 5525; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceMar 13, 20121
  • Filings158 in all: 10-Q (41), 8-K (36), 10-K (14), 3 (11), D (8), NT 10-Q (7), 4 (5), SC 13D (5)1
    All 21 form types

    UPLOAD (5), 8-K/A (4), D/A (4), NT 10-K (4), 10-12G/A (3), 10-K/A (3), 10-12G (2), CORRESP (1), DEF 14A (1), RW (1), SC 13G (1), SC 13G/A (1), SCHEDULE 13D (1)

  • Latest filingsAnnual report (10-K) Apr 15, 2026
    Quarterly report (10-Q) Aug 14, 2026
    Proxy statement (DEF 14A) Mar 23, 2018
    Latest 8-K (8-K) Aug 25, 2026

Securities registered for trading

ClassSymbolExchange
None

From the cover page of the 10-K filed Apr 15, 2026 (Section 12(b) of the Exchange Act).3

Risk factors and legal proceedings

The risks Nu-Med Plus, Inc. names in Item 1A of its 10-K filed Apr 15, 2026: 17 risks under these headings, as written.3

  • We currently do not have the capital to fund operations and are dependent on raising additional capital to stay in business.
  • We are still in the product development phase of our operations, so the ultimate success of our products is unknown.
  • Nitric oxide is a regulated chemical and is subject to extensive environmental regulations related to its handling and disposal, which may increase our costs and subject us to environmental regulations.
  • We may incur significant costs complying with environmental laws and regulations, and failure to comply with these laws and regulations could expose us to significant liabilities.
  • We will need additional financing, which will potentially dilute current investors, and we may not be able to obtain such financing.
  • The medical product business is highly competitive and subject to extensive regulations, making it difficult and very expensive to bring new products into the marketplace.
  • Our success will be dependent on the ability of management to develop medical devices.
  • Our success depends, in part, on our key personnel.
  • We May Be Subject to Product Liability Claims if People or Property Are Harmed by the Products We Sell.
  • Our auditors have indicated in their audit opinion that there is a substantial doubt about our ability to continue as a going concern, which will affect our ability to raise capital or borrow money.
  • We are a small Company with a limited number of employees, which makes it impossible to implement the internal controls that provide investors with assurances as to reporting accuracies.
  • General Risks Relating to Investors
The other 6 risks
  • We intend to take advantage of the disclosure requirements of the JOBS Act provided for emerging growth companies, including not providing all of the accounting disclosure that other companies will be required to provide, which may limit an investor’s ability to compare our financial statements with other companies.
  • We do not intend to pay dividends in the near future.
  • Investors will not have cumulative voting and will not be able to elect directors based on the percentages of ownership.
  • We may issue more stock without shareholder input or consent, which could dilute the book value of your investment.
  • A relatively small number of stockholders and managers have significant influence over us, other stockholders will not be able to have a voice in the direction of the company, and stockholders may disagree with the decisions of management.
  • The departure of certain key personnel could affect the financial condition of NU-MED due to the loss of their expertise.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32